HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shenhong Wu Selected Research

Neoplasms (Cancer)

6/2022Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.
5/2022Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.
2/2020Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis.
1/2019Emerging therapeutic agents for genitourinary cancers.
1/2019Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis.
1/2019Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis.
1/2018An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
1/2018Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
11/2017Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
9/2017Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shenhong Wu Research Topics

Disease

47Neoplasms (Cancer)
06/2022 - 01/2007
17Renal Cell Carcinoma (Grawitz Tumor)
12/2019 - 02/2008
11Hypertension (High Blood Pressure)
05/2022 - 02/2007
10Exanthema (Rash)
01/2015 - 01/2009
8Prostatic Neoplasms (Prostate Cancer)
01/2019 - 01/2007
5Breast Neoplasms (Breast Cancer)
02/2020 - 06/2011
4Neoplasm Metastasis (Metastasis)
10/2014 - 01/2007
4Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
08/2013 - 09/2008
3Melanoma (Melanoma, Malignant)
02/2020 - 03/2013
3Colorectal Neoplasms (Colorectal Cancer)
08/2013 - 01/2009
3Proteinuria
08/2011 - 02/2007
2Anemia
04/2015 - 10/2011
2Pruritus (Itching)
11/2013 - 03/2013
2Hepatocellular Carcinoma (Hepatoma)
08/2013 - 09/2008
2Multiple Myeloma
08/2013 - 01/2007
2Hemorrhage
08/2011 - 01/2010
1Bronchiolitis Obliterans Syndrome
06/2022
1Pneumonia (Pneumonitis)
02/2020
1Cardiotoxicity
02/2020
1Urinary Bladder Neoplasms (Bladder Cancer)
01/2019
1Disease Progression
01/2017
1Infections
11/2016
1Hyperglycemia
09/2016
1Obesity
11/2015
1Stomach Neoplasms (Stomach Cancer)
11/2015
1Heart Diseases (Heart Disease)
08/2015
1Edema (Dropsy)
08/2015
1Hypokalemia
08/2015
1Stomatitis
03/2015
1Neuroendocrine Tumors (Neuroendocrine Tumor)
06/2014
1Astrocytoma (Pilocytic Astrocytoma)
06/2014
1Sarcoma (Soft Tissue Sarcoma)
08/2013
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
08/2013
1Glioblastoma (Glioblastoma Multiforme)
02/2013
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
02/2013
1Alopecia (Baldness)
01/2013
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2011
1Heart Failure
06/2011
1Fatigue
01/2011
1Anorexia
01/2011
1Diarrhea
01/2011
1Hand-Foot Syndrome
01/2011

Drug/Important Bio-Agent (IBA)

9Angiogenesis InhibitorsIBA
08/2013 - 02/2007
9Bevacizumab (Avastin)FDA Link
10/2011 - 02/2007
8EverolimusFDA Link
09/2017 - 06/2014
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2011 - 02/2007
5Sunitinib (Sutent)FDA Link
12/2019 - 09/2008
4TOR Serine-Threonine KinasesIBA
04/2015 - 06/2014
4Tyrosine Kinase InhibitorsIBA
02/2013 - 01/2009
4Phosphotransferases (Kinase)IBA
02/2013 - 01/2008
3Pharmaceutical PreparationsIBA
05/2022 - 02/2008
3Axitinib (AG 013736)IBA
12/2019 - 06/2013
3abirateroneIBA
01/2019 - 08/2015
3Prednisone (Sone)FDA LinkGeneric
01/2019 - 08/2015
3IpilimumabIBA
01/2018 - 03/2013
3NivolumabIBA
01/2018 - 01/2017
3MTOR InhibitorsIBA
11/2016 - 01/2015
3temsirolimusFDA Link
11/2016 - 01/2015
3Docetaxel (Taxotere)FDA Link
08/2015 - 05/2007
3Antineoplastic Agents (Antineoplastics)IBA
03/2013 - 11/2008
3ErbB Receptors (EGF Receptor)IBA
11/2009 - 01/2009
3Sorafenib (BAY 43-9006)FDA Link
09/2008 - 01/2008
2Immune Checkpoint InhibitorsIBA
02/2020 - 01/2018
2pazopanibFDA Link
08/2013 - 08/2012
2Trastuzumab (Herceptin)FDA Link
09/2012 - 06/2011
2AndrogensIBA
09/2007 - 05/2007
2Diphosphonates (Bisphosphonates)IBA
09/2007 - 01/2007
1ibrutinibIBA
06/2022
1Biomarkers (Surrogate Marker)IBA
05/2022
1pembrolizumabIBA
02/2020
1avelumabIBA
12/2019
1erdafitinibIBA
01/2019
1enzalutamideIBA
01/2019
1Biological ProductsIBA
01/2018
1cabozantinibIBA
01/2017
1lenvatinibIBA
01/2017
1AcidsIBA
11/2015
1Interleukin-2 (IL2)IBA
09/2013
1CTLA-4 AntigenIBA
09/2013
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
08/2013
1Dexamethasone (Maxidex)FDA LinkGeneric
08/2013
1regorafenibIBA
08/2013
1Lenalidomide (CC 5013)FDA Link
08/2013
1VemurafenibIBA
03/2013
1Temozolomide (Temodar)FDA LinkGeneric
02/2013
1Dasatinib (BMS 354825)FDA Link
02/2013
1nilotinibFDA Link
02/2013
1Selective Estrogen Receptor Modulators (SERM)IBA
01/2013
1Estrogens (Estrogen)FDA Link
01/2013
1TamoxifenFDA LinkGeneric
01/2013
1Aromatase InhibitorsIBA
01/2013
1pertuzumabIBA
09/2012
1vandetanib (ZD6474)IBA
04/2012
1AnthracyclinesIBA
06/2011
1PlatinumIBA
08/2010

Therapy/Procedure

22Therapeutics
05/2022 - 01/2007
11Drug Therapy (Chemotherapy)
02/2020 - 11/2009
1Immunotherapy
01/2018
1Castration
08/2015
1Drug Tapering
01/2015